Lymphocyte DMA damage and total antioxidant status in patients with white-coat hypertension and sustained hypertension

Turk Kardiyoloji Dernegi Arsivi

Volumn 36, Issue 4, 2008, Pages 231-238

  Yildiz, Ali ^a   Gür, Mustafa ^a   Yilmaz, Remzi ^a   Demirbaǧ, Recep ^a   Çelik, Hakim ^a   Aslan, Mehmet ^a   Koçyiǧit, Abdurrahim ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Antioxidants metabolism; Blood pressure; Blood pressure monitoring, ambulatory; DNA damage; Hypertension; Lymphocytes; Oxidative stress

Indexed keywords

ANTIOXIDANT;

ARTICLE; BLOOD PRESSURE MONITORING; CASE CONTROL STUDY; COMET ASSAY; DNA DAMAGE; FEMALE; GENETICS; HUMAN; HYPERTENSION; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY;

ANTIOXIDANTS; BLOOD PRESSURE MONITORING, AMBULATORY; CASE-CONTROL STUDIES; COMET ASSAY; DNA DAMAGE; FEMALE; HUMANS; HYPERTENSION; LYMPHOCYTES; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 55849145556     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, et al. Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 1983;2:695-8.
2. Mancia G, Zanchetti A. White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? J Hypertens 1996;14:1049-52.
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
4. Gustavsen PH, Høegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. J Hum Hypertens 2003;17:811-7.
5. Muldoon MF, Nazzaro P, Sutton-Tyrrell K, Manuck SB. White-coat hypertension and carotid artery atherosclerosis: a matching study. Arch Intern Med 2000;160: 1507-12.
6. Owens PE, Lyons SP, Rodriguez SA, O'Brien ET. Is elevation of clinic blood pressure in patients with white coat hypertension who have normal ambulatory blood pressure associated with target organ changes? J Hum Hypertens 1998;12:743-8.
7. Palatini P, Penzo M, Canali C, Dorigatti F, Pessina AC. Interactive action of the white-coat effect and the blood pressure levels on cardiovascular complications in hypertension. Am J Med 1997;103:208-16.
8. Halliwell B, Aruoma OI. DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett 1991;281:9-19.
9. Ames BN. Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun 1989;7:121-8.
10. Botto N, Rizza A, Colombo MG, Mazzone AM, Manfredi S, Masetti S, et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 2001;493:23-30.
11. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56:69-83.
12. Andreassi MG, Botto N, Cocci F, Battaglia D, Antonioli E, Masetti S, et al. Methylenetetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. Hum Genet 2003;112:171-7.
13. Russo C, Olivieri O, Girelli D, Faccini G, Zenari ML, Lombardi S, et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens 1998;16:1267-71.
14. Prabha PS, Das UN, Koratkar R, Sagar PS, Ramesh G. Free radical generation, lipid peroxidation and essential fatty acids in uncontrolled essential hypertension. Prostaglandins Leukot Essent Fatty Acids 1990; 41:27-33.
15. Lee J, Lee M, Kim JU, Song KI, Choi YS, Cheong SS. Carvedilol reduces plasma 8-hydroxy-2′-deoxyguanosine in mild to moderate hypertension: a pilot study. Hypertension 2005;45:986-90.
16. Uzun H, Karter Y, Aydin S, Curgunlu A, Simsek G, Yucel R, et al. Oxidative stress in white coat hypertension; role of paraoxonase. J Hum Hypertens 2004; 18:523-8.
17. Pierdomenico SD, Costantini F, Bucci A, De Cesare D, Cuccurullo F, Mezzetti A. Low-density lipoprotein oxidation and vitamins E and C in sustained and white-coat hypertension. Hypertension 1998;31:621-6.
18. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994; 234:279-93.
19. Demirbag R, Yilmaz R, Kocyigit A. Relationship between DNA damage, total antioxidant capacity and coronary artery disease. Mutat Res 2005;570:197-203.
20. Demirbag R, Yilmaz R, Gur M, Kocyigit A, Celik H, Guzel S, et al. Lymphocyte DNA damage in patients with acute coronary syndrome and its relationship with severity of acute coronary syndrome. Mutat Res 2005;578:298-307.
21. Marcus R, Krause L, Weder AB, Dominguez-Meja A, Schork NJ, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 1994;90:928-36.
22. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring. 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005;46:508-15.
23. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
24. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37:7-11.
25. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-8.
26. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175:184-91.
27. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-9.
28. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002;105:2107-11.
29. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000;28:1815-26.
30. Romero JC, Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999;34:943-9.
31. Raij L. Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy. Hypertension 1998:31:189-93.
32. Chen LY, Nichols WW, Hendricks J, Mehta JL. Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysis. Am Heart J 1995;129:211-8.
33. Honda M, Yamada Y, Tomonaga M, Ichinose H. Kamihira S. Correlation of urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study. Leuk Res 2000;24:461-8.